FINWIRES · TerminalLIVE
FINWIRES

CIBCは、第1四半期決算発表を前に、エレメント・フリート・マネジメントの株価を「アウトパフォーム」に据え置き、目標株価を41.00ドルに設定した。

By

-- CIBCキャピタル・マーケッツは、エレメント・フリート・マネジメント(EFN.TO)の株式について、第1四半期決算発表を前に「アウトパフォーム」のレーティングと目標株価41.00カナダドルを維持した。 同行は、第1四半期決算が「堅調」になると予想している。CIBCは、新規融資とサービス収入が予想を上回れば、「株価の上昇モメンタムが回復する可能性がある」と考えている。 CIBCは、第1四半期の1株当たり利益(EPS)予想を0.34ドルで据え置き、市場コンセンサスとほぼ一致しており、前年同期比22%増となる見込みだと述べた。また、シンジケーション収入は前年同期比70%増と予測している。 アナリストのポール・ホールデン氏は、「2026年のEPS成長率15%と、もはや割高ではない株価収益率(P/E倍率)を前提に、『アウトパフォーム』のレーティングを維持する」と述べた。 「EFNが2025年と2024年の融資実行額目標を達成できなかったため、今後、融資実行額への注目度が高まることが予想されます。」 同行の第1四半期の収益予測は3億1400万ドルで、前年同期比14%増となる見込みです。また、第1四半期の費用は前年同期比7%増、営業利益率は57.6%と予測しています。

Price: $32.47, Change: $+0.13, Percent Change: +0.40%

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD